JAZZ News and Press, Jazz Pharmaceuticals plc From 01/06/20

DUBLIN , Jan. 6, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Bruce Cozadd , chairman and chief executive offic...

Stocks rallied significantly in the fourth quarter, and seasonality suggests there may be additional upside, but there's also an extreme number of stocks trading at least 5% above their 200-day moving average, and Middle East saber-rattling could cause uncertainty that leads to investors der...

The first participant has been enrolled in an open-label Phase 2/3 clinical trial evaluating Jazz Pharmaceuticals' (NASDAQ: JAZZ ) JZP-458 in pediatric and adult patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived enz...

Pivotal Phase 2/3 study is being conducted in collaboration with Children's Oncology Group DUBLIN , Dec. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in the pivotal Phase 2/3 clinical study for JZP-458, ...

Investment Thesis Notwithstanding the impressive sales growth and superior margins over the years, Jazz Pharmaceuticals plc ( JAZZ ) has risen only ~22% this year, compared to ~25% gain in the NASDAQ Biotechnology index. The market-leading position of its major revenue contributor, Xyr...

Jazz Pharmaceuticals ( JAZZ +0.9% ) inks an agreement with Spanish drug maker PharmaMar for exclusive U.S. rights to cancer med lurbinectedin, an inhibitor on oncogenic transcription (interferes with gene expression in cancer cells). More news on: Jazz Pharmaceuticals plc, Healthcare s...

- Jazz to pay an upfront payment of $200 million to PharmaMar - Opportunity for Jazz to expand its oncology portfolio with lurbinectedin , a late stage asset in relapsed small cell lung cancer (SCLC) - PharmaMar is also eligible to receive up to $800  mil...

Healthcare is a great industry to invest in because it can offer a lot of stability when economic challenges weigh down stocks in other industries. Medical innovation is always in demand and people will always need prescriptions, medical devices, and health services no matter the state of the ec...

For a pharmaceutical company that relies heavily on one product to generate revenue, the challenge from generic rival drugs can be devastating. That is the situation Jazz Pharmaceuticals (NASDAQ: JAZZ) might encounter in a few years' time. The company's top-selling product, the sleep disor...

Omeros (OMER) is nearing the launch of its potential blockbuster, Narsoplimab. The drug's first target is HSCT-TMA. The company expects to receive FDA approval in late-2020. This document is intended to review the competitive landscape of Narsoplimab in HSCT-TMA. This is in no way a thorou...